


**Use of excluded HCDs in the treatment of Axial Spondyloarthritis in adults.**

**Treatment pathway in line with NICE TAs 383, 407, 497, 718, 719, 829, 861, 918, 920 & local agreements**



<b>Version</b>	3.1
<b>Developed by</b>	Pharmacy and Medicines Optimisation Team, Hertfordshire and West Essex (HWE) ICB with relevant HWE ICS stakeholders.
<b>Approved by</b>	Hertfordshire & West Essex Area Prescribing Committee
<b>Date approved / updated</b>	November 2023
<b>Review Date</b>	This HWE APC recommendation is based upon the evidence available at the time of publication. This recommendation will be reviewed upon request in the light of new evidence becoming available.
<b>Superseded versions</b>	Use of excluded HCDs in the treatment of Axial Spondyloarthritis in adults. Treatment pathway in line with NICE TAs 383, 407, 497, 718, 719, 829 & local agreements. Version 1.0. HWE APC, February 2023 Pathway for use of biologic drugs for Axial Spondyloarthritis West Essex CCG MOPB, October 2021 Use of excluded HCDs in the treatment of Axial Spondyloarthritis in adults. Treatment pathway in line with NICE TAs 383, 407, 497, 718, 719, 829 & local agreements v1.0 February 2023 Use of excluded HCDs in the treatment of Axial Spondyloarthritis in adults. Treatment pathway in line with NICE TAs 383, 407, 497, 718, 719, 829, 861 & local agreements v 2.0 March 2023 (bimekizumab & tofacitinib added) Addition of price change or biosimilar wording for pathway updates agreed at June 24 APC

NICE recommends if patients and their clinicians consider a medicine to be one of a range of suitable treatments, the least expensive treatment should be chosen, taking into account administration costs, dosage, price per dose and commercial arrangements. Therefore, in line with this recommendation and HWE APC agreed principles the order of preference of treatments within this pathway will be updated accordingly as prices change or biosimilar medicines become available.